YAbS: The Antibody Society’s antibody therapeutics database DOI Creative Commons
Puneet Rawat, Silvia Crescioli, R. Prabakaran

et al.

mAbs, Journal Year: 2025, Volume and Issue: 17(1)

Published: Feb. 27, 2025

Therapeutic antibodies have gained prominence in recent years due to their precision targeting specific diseases. As these molecules become increasingly essential modern medicine, comprehensive data tracking and analysis are critical for advancing research ensuring successful clinical outcomes. YAbS, The Antibody Society's Therapeutics Database, serves as a vital resource monitoring the development progress of therapeutic antibodies. database catalogs detailed information on over 2,900 commercially sponsored investigational antibody candidates that entered study since 2000, well all approved therapeutics. Data late-stage pipeline therapeutics regulatory review or (over 450 molecules) openly accessible (https://db.antibodysociety.org). Antibody-related includes molecular format, targeted antigen, current status, indications studied, timeline antibodies, geographical region company sponsors. Furthermore, supports in-depth industry trends analysis, facilitating identification innovative developments assessment success rates within field. This is continually updated refined, providing invaluable insights researchers, clinicians, professionals engaged development.

Language: Английский

Quantifying antibody binding: techniques and therapeutic implications DOI Creative Commons
James Lodge,

Lewis Kajtar,

R. E. Duxbury

et al.

mAbs, Journal Year: 2025, Volume and Issue: 17(1)

Published: Feb. 16, 2025

The binding kinetics of an antibody for its target antigen represent key determinants biological function and success as a novel biotherapeutic. Defining these interactions is critical understanding the pharmacological pharmacodynamic profiles antibodies in therapeutic applications, with line sight to clinical translation. In this review, we discuss latest developments approaches measure modulate antibody-antigen interactions, including engineering, formats, current, emerging technologies measuring perspectives within field. We also explore how computational methods are set become powerful tools modeling antibody-binding under physiologically relevant conditions. Finally, consider implications modulating engagement terms pharmacodynamics pharmacokinetics.

Language: Английский

Citations

0
YAbS: The Antibody Society’s antibody therapeutics database DOI Creative Commons
Puneet Rawat, Silvia Crescioli, R. Prabakaran

et al.

mAbs, Journal Year: 2025, Volume and Issue: 17(1)

Published: Feb. 27, 2025

Therapeutic antibodies have gained prominence in recent years due to their precision targeting specific diseases. As these molecules become increasingly essential modern medicine, comprehensive data tracking and analysis are critical for advancing research ensuring successful clinical outcomes. YAbS, The Antibody Society's Therapeutics Database, serves as a vital resource monitoring the development progress of therapeutic antibodies. database catalogs detailed information on over 2,900 commercially sponsored investigational antibody candidates that entered study since 2000, well all approved therapeutics. Data late-stage pipeline therapeutics regulatory review or (over 450 molecules) openly accessible (https://db.antibodysociety.org). Antibody-related includes molecular format, targeted antigen, current status, indications studied, timeline antibodies, geographical region company sponsors. Furthermore, supports in-depth industry trends analysis, facilitating identification innovative developments assessment success rates within field. This is continually updated refined, providing invaluable insights researchers, clinicians, professionals engaged development.

Language: Английский

Citations

0